Journal
CURRENT ONCOLOGY REPORTS
Volume 14, Issue 2, Pages 111-119Publisher
SPRINGER
DOI: 10.1007/s11912-012-0225-0
Keywords
Fibroblast growth factor signaling; FGF; FGFR; Angiogenesis; Multitargeted receptor tyrosine kinase; Angiokinase inhibitors; BIBF 1120; Brivanib; Dovotinib; Breast cancer; AZD4547
Categories
Funding
- Cancer Research UK
- Experimental Cancer Medicine Centre
- National Institute for Health Research Biomedical Research Centre
Ask authors/readers for more resources
The fibroblast growth factor (FGF) signaling pathway is implicated as a key driver of tumor progression and growth via the dysregulation of cell proliferation, differentiation, survival, and angiogenesis in multiple tumor types. In addition, it may serve as a mechanism of resistance to antivascular endothelial growth factor targeted therapy. As such this pathway has emerged as a relevant therapeutic target, and several agents that can inhibit or modulate its signaling are in various stages of development. This review will summarize the current clinical status of agents targeting FGF receptors. In addition, strategies to accelerate the clinical development of these targeted agents will be presented.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available